



6th Annual Pain Management

Innovations in analgesia from genomics to human experimental models

14th - 15th October 2009, BSG Conference Centre, London, UK

BOOK NOW!

Key Speakers

Chas Bountra, Chief Scientist, Structural Genomics Consortium, **University of Oxford**

Kevin Lee, Vice President, Drug Discovery, **GlaxoSmithKline**

Edgar Adams, Executive Director of Epidemiology, **Covance**

Irene Tracey, Director, Oxford FMRIB Centre and Nuffield Professor of Anaesthetic Science, **University of Oxford**

Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, **Aalborg University**

Rolf Karlsten, Medical Science Director, **AstraZeneca**

Roger Pertwee, Director of Pharmacology, **GW Pharmaceuticals**

Stephen Wright, Research and Development Director, **GW Pharmaceuticals**

Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, **Merck, Sharp & Dohme**

Anastasia Liapi, Director, Business Development, **Astellas**

Theo F. Meert, Senior Research Fellow, Neuroscience, **Johnson & Johnson**

Steve England, Associate Research Fellow, **Pfizer**

Stephen Hammond, Chief Executive Officer, **Scottish Biomedical**

Stephen Peroutka, Vice President, Neurosciences, **PRA International**

William K. Schmidt, Vice President, Clinical Development, **CrystalGenomics**

Nathaniel Katz, President & Chief Executive Officer, **Analgesic Research**

Klaus Schaffler, Chief Executive Officer, **Human Pharmacodynamic Research**

Luda Diatchenko, Chief Scientific Officer, **Algynomics**

Platinum Sponsor

ims | INTELLIGENCE.
APPLIED.

Media Partners

 **pharmiweb.com**

 **BIOTECHNOLOGY - EUROPE**
your partner in innovation and business

 **FUTURE
PHARMACEUTICALS**

 **InPharm.com**

Organised By

To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/pain

visiongain

Conference Introduction

6th Annual Pain Management

14th - 15th October, 2009, London UK

Pain costs approximately €200m in Europe¹ and \$1trillion in the developed world in treatments, loss of productivity and disability payments². While therapeutic breakthroughs have been rare over the past 30 years, exciting advances are heralding much-needed and more effective analgesics^{2,3}. Modern lifestyles and an aging population will lead the global pain market, currently worth \$35bn, to increase by a forecast 65% to \$55bn by 2023³.

Dear Colleague,

With an estimated 100 billion tablets or 35,000 tons of aspirin consumed annually in the United States alone, pain management continues to be among the fastest growing sectors of the global pharmaceutical market. Yet pain-related conditions frequently lack effective therapy and there are few analgesic classes- all of which have safety issues. The attrition rate for new analgesics remains stubbornly high, and prospects for even the most effective animal-tested drug is 5%. The danger of addiction to opioids remains unresolved and patents are rapidly nearing their end. Chronic conditions such as spinal cord injury, neuralgias and phantom limb pain remain vast unmet needs, and the search for new analgesics continues unabated.

Industry is responding to the challenge, with over 40 new products in the pipeline and new opportunities for reformulated compounds, as well as generics and biologicals. Insights from genomics, molecular biology, neuroimaging and human experimental models are driving targeted therapies, from receptor antagonists and ion channel modulators, to monoclonal antibodies and novel NSAIDs, many of which are now in clinical trials.

By attending Visiongain's 6th Annual Pain Management conference, you will acquire distilled, market-focussed intelligence from outstanding speakers in key areas including:

- Rational approaches to chronic pain management with opioids and new FDA risk evaluation and mitigation strategy guidelines
- Clinical results from human experimental pain models in early drug development
- Genetic architecture of human pain perception and the molecular mechanisms underlying various types of pains
- New insights from voltage-gated sodium and calcium channel targets
- Emerging strategies in exploiting cannabinoid receptors agonists and their clinical results
- Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era
- Adequate PoC for new mechanisms
- Biomarkers for pain- from model to clinic
- Neuroimaging tools for analgesic drug discovery
- Reducing the numbers of patients in human clinical trials by eliminating non-responders
- Novel treatments for peripheral neuropathies undergoing clinical trials
- Outcome studies for neuropathic pain treatments in clinical practice and their implications for drug development and study design
- Innovative methods for conducting proof-of-concept studies
- Monoclonal antibody therapies for osteoarthritis in Phase III clinical trials
- Laser technology as a novel technique in human pain research
- The future market landscape in chronic pain
- New insights into migraine pain and the molecular basis of effective therapeutics

I look forward to meeting you at the conference

Best regards



John Shah
Conference Producer

Who should attend?

Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, and Professors in:

- Analgesia
- Neuropharmacology
- CNS Clinical Discovery/Nervous System Research
- Neuroscience
- Neurology
- Arthritis
- Migraine
- Medicinal Chemistry
- Healthcare
- Drug Discovery
- Emerging Targets/Lead Optimisation
- Therapeutics and Molecular Profiling
- Antibody Research and Development
- Protein Technologies
- Pre-Clinical/Clinical R&D
- Disease Genetics
- Genomics/Proteomics/Bioinformatics/Neuroinformatics
- Translational Medicine
- Imaging
- Clinical Trials
- Business Development
- Licensing and External Research
- Global Marketing and Medicine

Platinum Sponsor:



Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to pharmaceutical and healthcare industries. With \$1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimisation capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide

For further information please visit: www.imshealth.com

Media Partners:



PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US.

For further information please email: corporate@pharmiweb.com



BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world's biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities.

For further information please visit www.biotechnology-europe.com



Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide.

For further information please visit: www.futurepharmaus.com



InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus.

For further information please visit: www.In-Pharm.com

About visiongain:

Visiongain is a specialist business information company focused on providing cutting edge products and services across the Pharmaceutical/Biotech, Telecommunications, Defence and Finance sectors, which include reports, conferences, online daily news and offline news analysis and bespoke consultancy. With a commitment to innovation and excellence, visiongain offers flexible solutions to meet our clients' business intelligence needs, providing the right information at the right time to facilitate the commercial decision-making process. Our pharmaceutical products include Pharma Business Daily, the leading daily email newsletter for the pharmaceutical, biotech and healthcare industries, and a range of independent, high-quality, in-depth reports covering focused and topical areas of concern. Our pharmaceutical conferences address the hottest commercial, regulatory and technical topics and provide an ideal forum for debate and networking for pharmaceutical professionals from around the world.

For further information, please visit: www.visiongain.com

Sponsorship and exhibition opportunities:

This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:

- Hosting a networking drinks reception
- Taking an exhibition space at the conference
- Advertising in the delegate documentation pack
- Providing branded bags, pens, gifts, etc.

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's 6th Annual Pain Management 2009 conference, please contact us:

Ronald Reyes Magali, +44 (0)20 7549 9934

ronald.magali@visiongainglobal.com

¹ Tracey, I. (2008). Prof. Irene Tracey on fMRI and pain. Downloaded from the World Wide Web on April 8th, 2009: <http://wspain.blogspot.com/2008/10/prof-irene-tracey-on-fmri-and-pain.html>.

² Max, M.B. and Stewart, W.F. (2008). Molecular Epidemiology of Pain: A New Discipline for Drug Discovery. *Nature Reviews Drug Discovery*, 7 (8), pp. 647-658.

³ Visiongain, (2008). *The Global Pain Market, 2008-2023*.

09:20 Registration and refreshments

09:50 Opening address from the chair

Chas Bountra

Chief Scientist, Structural Genomics Consortium

University of Oxford

Formerly Vice President & Head, Biology, **GlaxoSmithKline**

10:00 The chronic pain market: building a roadmap to commercial success

- The market dynamics in key chronic pain indications
- Positioning your product in the pain market: when R&D meets marketing
- The future market landscape in chronic pain: gazing into the crystal ball and not seeing black swans

Anastasia Liapi

Director, Business Development

Astellas

10:40 Genetic architecture of human pain perception

- Pain perception is one of the most complex measurable traits and an aggregate of many intermediate phenotypes
- Genetic variation and environmental events mediate human pain phenotypes
- Separate vulnerability pathways underlie patient heterogeneity in chronic pain

Luda Diatchenko

Chief Scientific Officer

Algenomics

11:20 Morning refreshments

11:40 Ion channel targets to discover analgesics

- Contribution/importance of different ion channels (IC) in pain
- Developing in vitro assays, stable cell lines over-expressing recombinant human IC and DRGs
- Current assay methodologies to discover novel analgesics

Stephen Hammond

Chief Executive Officer

Scottish Biomedical

12:20 Voltage-gated sodium channels as targets for novel analgesics

- Importance of Navs in pain signalling
- Nav1.7; supporting evidence from human genetic studies
- Future prospects for finding subtype-selective compounds

Steve England

Associate Research Fellow

Pfizer

13:00 Networking lunch

14:20 TRPV1 antagonists as drug targets

- TRPV1 agonists: mechanism of action
- Topical vs. systemic application of TRPV1 agonist
- Pungency prediction of TRPV1 agonists

Ronald Palin

Medicinal Chemist

Schering-Plough*

15:00 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era

- What have we learned about GI and cardiovascular risk?
- What strategies are being employed to improve GI and cardiovascular safety?
 - Example #1: Naproxenolol, a nitric-oxide donating analog of naproxen
 - Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase
- Are regulatory hurdles manageable in the USA and Europe?

William K. Schmidt

Vice President, Clinical Development

CrystalGenomics

15:40 Afternoon refreshments

16:00 Emerging strategies in exploiting cannabinoid receptors agonists

- A current strategy for targeting cannabinoid receptors
- Emerging strategies for targeting cannabinoid receptors
- Results from clinical trials

Roger Pertwee

Director of Pharmacology

GW Pharmaceuticals

Stephen Wright

Research and Development Director

GW Pharmaceuticals

16:40 Pain management in the 21st century: where are we and what are the prospects for the future?

Topics will include: the brain's role in pain, new targets for the future, and peripheral mechanisms in analgesia and side-effect management. Pharmacovigilance and the role of pricing and reimbursement will also be discussed. If you would like to submit a question to the panel, please email: john.shah@visiongainglobal.com.

Chair:

Chas Bountra, Chief Scientist, Structural Genomics Consortium, **University of Oxford**, Formerly Vice President & Head, Biology, **GlaxoSmithKline**

Kevin Lee, Vice President, Drug Discovery, **GlaxoSmithKline**

Anastasia Liapi, Director, Business Development, **Astellas**

William K. Schmidt, Vice President, Clinical Development, **CrystalGenomics**

Nathaniel Katz, President, **Analgesic Research**

PANEL DISCUSSION

17:20 Closing remarks from the chair

17:30 Networking Drinks Reception
Take your discussions further and build new relationships in a relaxed and informal setting.

- 09:20 Registration and refreshments
- 09:50 Opening address from the Chair
Chas Bountra
 Chief Scientist, Structural Genomics Consortium
University of Oxford
 Formerly Vice President & Head, Biology, **GlaxoSmithKline**
- 10:00 Migraine pain: what have we learned to date?
 • To review previous and current theories of the origin of migraine pain
 • To assess the clinical relevance of the various hypotheses
 • To suggest an unifying mechanism to explain migraine pain as well as the molecular basis of effective therapeutics
Stephen Peroutka
 Vice President, Neurosciences
PRA International
- 10:40 Development of treatments for peripheral neuropathies
 • Existing treatment options
 • Preclinical research
 • Growth factors
 • POC modeling in humans
Theo F. Meert
 Professor, **Katholieke Universiteit Leuven and University of Antwerp**
 Senior Research Fellow, Neuroscience, **Johnson & Johnson***
- 11:20 Morning refreshments
- 11:40 Outcome of treatment in neuropathic pain in clinical practice - its implication for drug development and study design
Rolf Karlsten
 Medical Science Director
AstraZeneca
- 12:20 Chronic pain management with opioids: a rational approach
 • Foundations of opioid risk management
 • Abuse-deterrent formulations: are they a pipe dream?
 • New FDA guidelines for risk evaluation and mitigation strategies
Edgar Adams
 Executive Director of Epidemiology
Covance
- 13:00 Networking lunch
- 14:00 A new potent opioid with fast return to normal GI transit
 • Neo1509 is an original opioid which exhibits a full return to normal GI transit during analgesia
 • Long duration of action (10 to 12 hours bolus, iv and po), as potent as morphine, no addiction in place preference assays
 • Currently in regulatory preclinical development
Roger Lahana
 Chief Executive Officer
Neorphys
- 14:20 Human experimental pain models in early drug development
 • Translation from animal to human pain models
 • Back-translation from human models to animal models
 • Translating from human experimental pain models in volunteers to pain patients
 • Mechanisms based proof-of-concept studies
 • The concept of multi-model, multi-tissue pain models
 • Integrating pain models in phase Ib studies
Lars Arendt-Nielsen
 Director, Pain Research Group, Centre for Sensory-Motor Interaction
Aalborg University
- 15:00 Developing imaging tools for analgesic drug discovery
 • Overview of tools available and what they measure
 • Examples relating to sensitivity and mechanism of action
 • Discussion of where they "sit" in the drug discovery process
Irene Tracey
 Director, Oxford FMRI Centre and Nuffield Professor of Anaesthetic Science
University of Oxford
- 15:40 Afternoon refreshments
- 16:00 Innovative methods for conducting proof-of-concept studies
 • Tools to reduce sample sizes by:
 - Identifying accurate pain reporters
 - Measuring pain more precisely
 - Measuring physical activity objectively
Nathaniel Katz
 Director, Program on Opioid Risk Management,
Tufts University School of Medicine,
 President & Chief Executive Officer, **Analgesic Research**
- 16:40 Laser technology as a novel technique in pain research
 • Principles of laser technology in pain research
 • Skin types/models to work with laser stimulation
 • Validity and reproducibility of laser stimuli - ending in a database on analgesics
Klaus Schaffler
 Research Professor, **University of Waterloo**
 President, **Human Pharmacodynamic Research**
- 17:20 Alternative approaches to proof-of-concept studies
 Panellists will discuss issues raised in the four preceding talks concerning the development of human experimental trials for novel analgesics. If you would like to submit a question to any of the participants, please email: john.shah@visiongainglobal.com.
Chas Bountra, Chief Scientist, Structural Genomics Consortium
University of Oxford, Formerly Vice President & Head, Biology, **GlaxoSmithKline**
Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, **Aalborg University**
Nathaniel Katz, President, **Analgesic Research**
Klaus Schaffler, Research Professor, **University of Waterloo**, President, **Human Pharmacodynamic Research**
Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, **Merck, Sharp & Dohme**
- 17:50 Chair's closing remarks and end of conference

Registration Form

6th Annual Pain Management

14th - 15th October, 2009, London UK

For multiple bookings

Photocopy this form

Conf. code **VG**

Standard Prices

Conference only Fee: £1299 VAT: £194.85 Total: £1493.85
Academic rate Fee: £499 VAT: £74.85 Total: £573.85

Promotional Literature Distribution

Distribution of your company's promotional literature to all conference attendees
 Fee: £999 VAT: £149.85 Total: £1148.85

Details

Forename: Surname:

Job Title: Company:

Main Switchboard Number:

Address:

Country: Postcode:

Phone: Fax:

Email:

Signature:

I confirm that I have read and agree to the terms and conditions of booking

Methods of payment

Payment must be made in sterling

By Mail: Complete and return your signed registration form together with your cheque payable to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK

By Fax: Complete and fax your signed registration form with your credit card details to +44 (0) 20 7549 9932

By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details

By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932

By Bank Transfer:

Visiongain Ltd A/C: visiongain Ltd
 Barclays Bank Sort Code: 20-71-64
 Piccadilly Branch Account No: 6038 7118
 48 Regent Street Swift Code: BARC GB22
 London W1B 5RA, UK IBAN: GB80 BARC 20716460387118

Please debit my credit card:

Access MasterCard Visa American Express

Card number:

Expiry Date:

Security number (last 3 digits on back of credit card):

Signature:

Cardholder's name:

News updates


Please tick if you do not want to receive email news updates in the future

6th Annual Pain Management

14th - 15th October 2009

Location: BSG Conference Centre

Address:
 226-236 City Road
 London
 EC1V 2TT
 UK



How to book

Email: conferences@visiongainglobal.com

Web: http://www.visiongain.com/pain

UK Office:

Tel: +44(0) 20 7336 6100
Fax: +44(0) 20 7549 9932

Visiongain Ltd
 BSG House
 226-236 City Road
 London
 EC1V 2QY
 UK

General information

Venue: Directions: BSG Conference Centre 226 - 236 City Road, London, EC1V 2TT. United Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340

Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices.

Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organisation and are not transferable between countries.

Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.

Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses.

Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1988. Your personal information contained in this form may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect.

Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).

VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT.

How we will contact you: Visiongain Ltd's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.

Unable to attend

Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will receive your copy of the event CD Rom two weeks after the event.

Yes, please send me a copy of the CD for Price£550 VAT:£82.50 Total:£632.50

Office use only

A B C D E F G H I J K L M